Conatus Pharmaceuticals Inc. (CNAT) Rating Reiterated by Brean Capital
Brean Capital restated their buy rating on shares of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) in a report released on Tuesday morning. They currently have a $7.00 price objective on the biotechnology company’s stock.
Several other brokerages also recently issued reports on CNAT. Zacks Investment Research raised shares of Conatus Pharmaceuticals from a hold rating to a buy rating and set a $2.25 price objective for the company in a research report on Tuesday, October 4th. FBR & Co reaffirmed an outperform rating and issued a $16.00 price objective on shares of Conatus Pharmaceuticals in a research report on Tuesday, August 30th. Finally, Roth Capital initiated coverage on shares of Conatus Pharmaceuticals in a research report on Friday, July 1st. They issued a buy rating for the company. Six investment analysts have rated the stock with a buy rating, Conatus Pharmaceuticals has an average rating of Buy and an average price target of $9.21.
Shares of Conatus Pharmaceuticals (NASDAQ:CNAT) opened at 1.99 on Tuesday. Conatus Pharmaceuticals has a 12 month low of $1.40 and a 12 month high of $4.62. The stock’s 50 day moving average is $1.93 and its 200 day moving average is $2.23. The stock’s market cap is $43.92 million.
Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its quarterly earnings data on Wednesday, August 3rd. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.38) by $0.08. During the same quarter last year, the company posted ($0.31) earnings per share. Analysts predict that Conatus Pharmaceuticals will post ($1.34) earnings per share for the current fiscal year.
A number of hedge funds have recently modified their holdings of CNAT. AXA increased its stake in shares of Conatus Pharmaceuticals by 1.4% in the second quarter. AXA now owns 1,085,775 shares of the biotechnology company’s stock valued at $2,237,000 after buying an additional 14,939 shares during the period. Vanguard Group Inc. increased its stake in Conatus Pharmaceuticals by 3.5% in the second quarter. Vanguard Group Inc. now owns 448,938 shares of the biotechnology company’s stock worth $925,000 after buying an additional 15,300 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Conatus Pharmaceuticals by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 86,296 shares of the biotechnology company’s stock worth $178,000 after buying an additional 1,668 shares during the last quarter. 22.80% of the stock is owned by institutional investors.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.